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ABSTRACT
Objective: To assess the effectiveness of MDMA-assisted psychotherapy in treating patients with
chronic refractory PTSD using a systematic review.
Methods: Literature search was performed on PubMed and PsychINFO using search terms “PTSD”
and “MDMA” to identify randomized control trials within the past 10 years.
Results: Two out of the three studies found statistically significant data in the treatment of
refractory PTSD. Mithoefer, M. et al and Ot’alora, M. et. al found a statistically significant decrease in
CAPS-IV total scores, decrease in depression symptoms, decreased in dissociative symptoms, and
increase in sleep quality.
Conclusion: The use of MDMA-assisted psychotherapy may be beneficial in treating chronic PTSD
patients who have failed previous treatment methods. Additional studies with a larger sample size
are necessary to determine the efficacy of MDMA-assisted psychotherapy in treating chronic PTSD.

INTRODUCTION
Although humans evolved by overcoming stressful situations and surviving life-threatening
events, some experiences overwhelm our coping mechanisms and alter our physiologic functioning.
In post-traumatic stress disorder (PTSD), a traumatic event elicits a series of complex adaptations
including a persistent avoidance of triggers, intrusive thoughts/memories, negative changes in
cognition, and alterations in arousal.1,2 All of these adaptations can significantly impact a person’s
ability to function on a daily basis, placing a large burden on one’s personal, professional, and social
life. A large majority of our population is at risk due to the multitude of common traumatic events
that have been highly associated with the development of PTSD. Currently, the lifetime prevalence
of PTSD in the United States and Canada ranges from 6.1 to 9.2 percent with a higher incidence
among sexual violence victims, combat veterans, childhood abuse victims, family members with
deceased or dying loved ones, and survivors of life-threatening accidents or injuries.3,4
The physiologic mechanisms underlying the development of PTSD are not well understood,
so treatment options focus on symptomatic relief rather than physiologic abnormality correction.
Treatment options for patients diagnosed with PTSD include psychotherapy or serotonergic
reuptake inhibitors (SRI) depending on patient preference, treatment availability, and past
treatment’s effectiveness.5,6,7 Research has shown psychotherapy to have clinically significant
symptom improvement; however, patients continue to meet diagnostic criteria for PTSD after
completion. Psychotherapy is also associated with a high dropout rate due to symptom worsening
and hospital admission.6 SRIs are shown to modestly improve avoidance and alterations in arousal,
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but do not improve intrusive symptoms.8 Considering intrusive symptoms are a detriment to most
patients with PTSD and the long-term impact of psychotherapy is minimal, current treatment
options are not appropriately managing PTSD symptoms. Therefore, researchers are currently
performing clinical trials on other treatment options that may be more effective. One of the current
treatment options undergoing clinical trials is 3,4-Methylenedioxymethamphetamine (MDMA)assisted psychotherapy.6,7
MDMA is a sympathomimetic amphetamine that stimulates serotonin, dopamine, and
norepinephrine release, as well as inhibits serotonin reuptake.7 By increasing serotonin levels,
MDMA is providing the same basic pharmacologic effects as SRIs. However, MDMA is thought to
exceed SRIs by also increasing dopamine, which induces a positive emotional/mental state and
reduces fear. Utilizing MDMA during psychotherapy sessions may improve the psychotherapeutic
process by allowing the patient to process traumatic events openly and associate with them
positively.7 Therefore, the purpose of this review is to assess the effectiveness of MDMA-assisted
psychotherapy on reducing PTSD severity in patients diagnosed with chronic PTSD compared to an
“active” placebo control.
CLINICAL QUESTION
In men and women ≥ 18 years old diagnosed with chronic PTSD with an inadequate
response to at least 1 pharmacotherapy or psychotherapy, does MDMA compared to an “active”
placebo decrease severity of PTSD?
METHODS
In September 2019, a literature search was performed on PubMed and PsychINFO to
identify randomized control trials utilizing MDMA to treat PTSD with comparable control groups.
Using the search terms “PTSD” and “MDMA,” a total of 333 articles were identified. Approximately
62 articles were screened of which 53 were excluded due to lack of relationship to topic and format
as an academic review rather than a research article. Of the 9 remaining articles fully assessed for
eligibility, 6 articles were excluded due to inappropriate study format (case control, cohort, or
follow-up study rather than randomized control trial) and incomparable control groups. Therefore,
only 3 articles fulfilled the criteria to analyze the efficacy of MDMA in treating chronic PTSD.
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Figure 1. PRISMA Flow Diagram.

RESULTS
Study #1:
A randomized controlled, pilot study of MDMA-assisted psychotherapy for treatment of resistant,
chronic PTSD. Oehen P, et al.
Objective: To evaluate the use of MDMA assisted psychotherapy as a treatment for chronic PTSD
patients and the use of 25mg of MDMA as an “active placebo” in order to maintain blinding during
the treatment.
Study Design: This was a randomized controlled pilot study of 14 recruited subjects from
psychiatric hospitals, trauma counseling centers, psychiatrist and psychotherapist in Switzerland
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for MDMA-assisted psychotherapy treatment of resistant, chronic PTSD. Table 1 outlines inclusion
and exclusion criteria.

Inclusion Criteria

DSM-IV Criteria for PTSD with treatment resistant symptoms: Clinician Administered
PTSD Scale (CAPS)* score of ≥50
Previously undergone at least 6 months of psychotherapy and 3 months of treatment
with a SSRI
Structured Clinical Interview for the DSM-IV Axis I and II Disorders (SCID I and II)
diagnosis of PTSD

Exclusion

Significant medical conditions, except for hypothyroidism under hormonal replacement

Criteria
Psychiatric conditions: history of psychotic illness, bipolar disorder type I, borderline
personality disorder, dissociative identity disorder, and substance abuse or dependence
within 60 days of enrollment

Subjects who had taken MDMA on more than five occasions or less than 6 months prior
to enrollment.
Table 1: Inclusion and exclusion criteria for Study #1 (Oehen P, et al). *Please refer to appendix A.

A full dose of 125mg MDMA, followed 2.5 hours later by 62.5mg MDMA was compared to
the active placebo of 25mg MDMA, followed 2.5 hours later by 12.5mg MDMA. The 14 subjects
underwent double blind randomization. 9 subjects were in the full dose group; 5 were placed in the
active placebo group. 2 subjects (1 from each group) withdrew after adverse effects of the first
MDMA session. The study was designed in three stages.
Stage 1 included subject given 3 full dose MDMA and 3 active placebo dose MDMA with 3 all
day long MDMA assisted psychotherapy sessions and 12 non-drug therapy sessions. Clinician
Administered PTSD Scale (CAPS) and Structured Clinical Interview for the DSM-IV Axis I Disorders
(SCID-I) substance abuse module were administered at baseline, 3 weeks after MDMA session
number 2, 3 weeks after MDMA session number 3, and at 2, 6, 12-month intervals after the MDMA
session number 3. Posttraumatic Diagnostic scale (PDS) was administered at one day after each
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MDMA session, 3 weeks after the third MDMA session, and at 2, 6, 12-month intervals after the
third MDMA session. All of the outcome measurements were done by independent raters.
Stage 2 of the experiment allowed the active placebo subjects the option to switch over to
the full dose MDMA. This open label broke the blind. All 4 subjects chose to enter the open label.
These subjects underwent 3 full dose MDMA sessions and 12 non-drug psychotherapy sessions. The
CAPS scores from the 3-week post active placebo MDMA session number 3 was used as baseline for
Stage 2. CAPS and PDS were completed at 2,6,and 12 months after the final MDMA session.
Stage 3 was created as an amendment to protocol for subjects who showed insufficient
clinical response to experimental full doses following preliminary data analysis. Insufficient clinical
response included: CAPS score changes ≤15 from baseline to 2 months post MDMA experimental
session number 3, CAPS item #25 ≥3, and overall CAPS score still ≥ 50 2 months after the third
MDMA session, and investigator and patients’ subjective interpretation of lack of improvement.
This allowed 2 additional MDMA assisted psychotherapy sessions and 7 non-drug psychotherapy
sessions. 3 subjects participated in this stage. The subjects were given 150mg MDMA and a
supplemental dose of 75mg MDMA.
The CAPS and PDS scores were analyzed via ANOVA comparing stage 1 and stage 2
(primary outcome). Wilcoxon signed-rank test was used for CAPS data collected from stage 2 and
stage 3. P value was set to a significance of 0.05.
Study Results: The full dose group showed a substantial decrease in CAPS scores compared to the
active placebo group but missed statistical significance (p = 0.066). The full-dose subjects had on
average a 15.6-point (23.5%) reduction on their CAPS score. The simple effect of time in the full
dose group was significant (p = 0.002), while the active placebo group did not show a significant
simple effect of time (p = 0.475). The PDS scores decreased in the full-dose group, while the PDS
score increased in the active placebo group. The PDS scores revealed a significant interaction effect
of group and time (p = 0.014). There was a significant decrease in CAPS score between the 3 weeks
post MDMA session #2- and 3-weeks post MDMA session #3 (p = 0.016), thus showing three MDMA
sessions were more effective than two. No medical intervention was used during the MDMA
sessions and no serious drug-related side effects occurred.
Study Critique: This study was groundbreaking for the first time use of an active placebo in order
to increase the blinded effects of the study compared to prior MDMA assisted psychotherapy
studies. The use of the active placebo did help the previous issues of the double-blind experiment
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but this study allowed patients to cross over into the full dose groups. This limited the statistical
data that could be used for comparing the effects of full-dose and active placebo. The 12 months
follow up showed a continuous reduction of CAPS scores in all individuals, but statistical
significance was unable to be determined due to the fact that all subjects crossed over to the fulldose losing the ability to compare between active placebo and full-dose.
An unexpected outcome from the study was the increase in PDS scores following the active
placebo dose. The patients clinically had the negative issues of PTSD but no positive benefits from
the MDMA. This suggests that partial activation of the MDMA occurred causing vivid memories and
emotions of the traumatic events but did not help the subjects view this state differently as the fulldose subjects did. This caused the subjects to have an increased need for the therapist help and
cause one patient to drop out due to fear of occurrence.
Overall, this study did not find statistical significance of their primary outcome in the use of
MDMA-assisted therapy. The study was done safely and subjects reported a decrease in symptoms.
There is promising information Further studies are necessary to evaluate the use of MDMA in the
treatment of refractory PTSD patients.
Study #2:
“3,4-methylenedioxymethamphetamine(MDMA)-assisted psychotherapy for post-traumatic stress
disorder in military veterans, firefighters, and police officers: a randomized, double-blind, doseresponse, phase 2 clinical trial.” Mithoefer, M. et al
Objective: The purpose of this study was to assess the efficacy and safety of MDMA-assisted
psychotherapy in military veterans, firefighters, and police officers with PTSD that developed due
to their time of service. This study also wanted to verify the results of two previous clinical trials of
MDMA-assisted psychotherapy that showed large effect sizes, low dropout rates, and long-lasting
improvements.
Study Design: This study is a double-blind, randomized, dose response phase 2 clinical trial at an
outpatient psychiatric clinic in Charleston, SC. The subjects were recruited via referrals from mental
health providers, advertisements, and word of mouth. 22 subjects were selected following the
inclusion and exclusion criteria listed in table 2. The selected subjects consisted of 22 veterans, 3
firefighters, and 1 police officer.
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Inclusion Criteria

18 years and older
Female or male veterans, firefighters, or police offices suffering with chronic PTSD
resulting from traumatic experiences during their service
PTSD duration of 6 months or more
CAPS score of ≥ 50
Failure to respond to or inability to tolerate previous pharmacotherapy or
psychotherapy

Exclusion Criteria

Major medical conditions except controlled hypertension or adequately treated
hypothyroidism
Pregnant or lactating women or women not using effective contraception
Bipolar disorder type 1

Table 2: Inclusion and exclusion criteria for Study #2 (Mithoefer, M. et al).

The study separated the participants into a total of three groups. A 75mg MDMA full-dose,
125mg MDMA full-dose, and 30mg MDMA active control. The subjects were randomly assigned to
their respective group 24 hours before the first experimental MDMA session. Three 90-minute
psychotherapy sessions were done prior to the first MDMA session to establish trust with the
providers and educate the subjects about the MDMA experience. There were two blinded sessions
that occurred 3-5 weeks apart. During these, the initial dose was given to the participants and 1.5-2
hours later were given the options of a supplemental dose of half the initial dose. The subjects
stayed overnight immediately following the session for precautions, then contacted 7 days later via
telephone, and a total of three 90-minute psychotherapy sessions. MDMA was administered during
the 8-hour experimental sessions at monthly intervals. Outcome measurements were administered
at baseline and 1 month after the second experimental session right before the blind was broken
(primary endpoint). Primary outcome included the mean change in CAPS total score. In summary,
the subjects underwent 18 hours of psychotherapy and 16-24 hours of MDMA assisted
psychotherapy. After the end of the primary endpoint, the subjects assigned to the 125mg MDMA
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had one additional open-label session and integrative visits within 3-5 weeks of the previous
blinded MDMA session. Outcome measurements were taken at the 2 months follow up visit. This
concluded the stage 1 of the experiment.
The subjects that were assigned 30mg and 75mg MDMA crossed over to have 3 open-label
sessions of flexible dosing of MDMA (100-125mg) within 5 months of the primary endpoint. The
open label sessions were spaced a month apart and included integrative visits. Outcome
measurements were taken 2 months after the 3 sessions (secondary endpoint), ending stage 2. Data
was also collected at the 12-month follow up of all the participants. The secondary outcomes
included BDI-II, PSQI, PTGI, NEO-PI-R, DES-II, and GAF (Table 3).

CAPS-IV

Clinician Administered PTSD Score for DSM-IV. (See Appendix A)

BDI-II

Beck Depression Inventory-II

PSQI

Pittsburgh Sleep Quality Index

PTGI

Post-Traumatic Growth Inventory

NEO-PI-R

Neuroticism- Extroversion-Openness-Personality Inventory-Revised

DES-II

Dissociative Experiences Scale II

GAF

Global Assessment of Functioning
Table 3: Secondary outcome definitions.

The efficacy of the dose response and secondary outcomes were analyzed on the intention
to treat population using ANOVA and pre-planned t tests. The cross over open label data used
scores of the primary endpoint, stage 2 secondary endpoint, and 12-month follow-up to baseline.
Study Results: The primary outcomes are included in table 4. The 75mg and 125mg group showed
a significant difference in PTSD symptom severity compared to the 30mg MDMA active control
group. There was no significant difference between the 75mg and 125mg groups (p = 0.185). At the
primary endpoint, many subjects no longer met the PTSD criteria with the CAPS score. 86% in the
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75mg group and 58% of the 125mg did not meet PTSD criteria, compared to 29% in the 30mg
group.
MDMA mg dose group

Mean change in CAPS IV total score (SD)

P-value

30mg

-11.4 (12.7)

NA

75mg

-58.3 (9.8)

0.0005

125mg

-44.3 (33.8)

0.004

Table 4: Primary Outcome – Mean change in CAPS total score from baseline to 1 month after the 2nd
blinded experimental session of MDMA assisted psychotherapy.

After two active doses of MDMA, a 30% CAPS score decrease or more was reached by 100%
of the 75mg group, 67% of the 125mg, and 29% of the 30mg group. The results from the secondary
outcomes are in table 5. The BDI-II (depression) was significantly reduced in the 125mg group
compared to the 30mg group but was not significant between the 75mg and 30mg. Sleep quality as
well as dissociative symptoms significantly improved during the course of treatment in the full dose
group compared to the active control dose group. PTGI scores increased in the active MDMA doses.
PTGI measures the ability of the subject to view themselves, others, and life events in a more
positive way, thus showing the potentially benefits beyond solely PTSD symptom reduction. The
GAF scores in the active dose group, revealed a significant improvement in psychological,
occupation, and social function compared to the placebo group. There was statistical significance in
personality trait changes such as a reduced neuroticism and increased openness, in the 125mg and
75mg groups respectively. These positive significant changes in the subjects continued to improve
over the 12 months.
In the 30 mg MDMA active control subjects that crossed over to the 2 open label sessions of
100-125mg, CAPS total score revealed an additional 27-point average decline. However, after the
3rd open label session, 50% of these individuals no longer qualified as having PTSD, which was
more than the other groups. The 30mg MDMA active control group was actually found to have
counter-therapeutic effects, thus making them harder to treat.
Study Critique: This study was a well-designed randomized, double blind, dose response pilot
control study. The results showed that the 75mg and 125mg MDMA active doses significantly
improved PTSD symptoms in veterans and first responders that have previously been refractory to
9
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treatment. This study further proves the significant findings in other studies of MDMA-assisted
psychotherapy.
Secondary Outcome

30mg

75mg

125mg

Change†

–4·6 (8·8)

–15·4 (9·5)

–24·6 (10·6)

p value‡

NA

0·052

0·0003

Change†

1·8 (2·8)

–6·4 (7·1)

–4·8 (4·1)

p value‡

NA

0·01

0·02

Change†

–11·6 (12·2)

36·1 (12·0)

33·7 (24·0)

p value‡

NA

<0·0001

<0·0001

Change†

1·1 (4·6)

19·4 (6·1)

18·4 (14·4)

p value‡

NA

0·004

0·002

Change†

1·8 (0·9)

–8·6 (1·9)

–8·8 (6·2)

p value‡

NA

0·02

0·01

Change†

–4·6 (5·5)

–12·0 (3·6)

–16·5 (11·8)

p value‡

NA

0·23

0·03

Change†

2·2 (4·3)

10·0 (9·4)

8·0 (9·4)

p value‡

NA

0·17

0·22

Change†

–0·6 (9·9)

15·6 (5·3)

2·0 (10·5)

p value‡

NA

0·02

0·62

Change†

–1·2 (8·4)

5·4 (8·0)

5·9 (4·9)

p value‡

NA

0·13

0·05

Change†

–3·2 (7·9)

2·4 (15·0)

6·5 (13·4)

p value‡

NA

0·50

0·17

Mean BDI-II score

Mean PSQI

Mean PTGI score

Mean GAF score

Mean DES-II score

Mean NEO-PI-R score
Neuroticism

Extroversion

Openness

Agreeableness

Conscientiousness
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Table 5: Secondary outcome results. *All outcomes are based on the intention-to-treat population.
†Change from baseline. ‡Compared with 30 mg MDMA.

The study sample size is small and could possibly skew data. The active control dose did
improve the study blind as compared to previous studies, but still came with issues. The study
collected data on the therapists’ and participants’ guess of the dose they were receiving. The
therapists incorrectly guessed 42.6% of the sessions and the participants incorrectly guessed
42.6% of the time. Thus, showing partial blinding was intact, but there is still evidence that it did
not work leading to possible bias and limitations of the study. The researchers attempted to
preserve the study blind by the use of an observer blind that rated independent outcomes not
present during the sessions.
The participants crossed over to the open label, thus every single subject received at least
one full dose of MDMA. The 12-month follow up data was then unable to be compared to the control
group, as no control group existed at this point of time. This leaves speculation as to a long-term
benefit from the 30mg dose.
Study 3
3,4-Methylenedioxymethamphetamine-assisted psychotherapy for treatment of chronic posttraumatic
stress disorder: a randomized phase 2 controlled trial. Ot’alora et al.
Study Objective: The purpose of the study was to evaluate the safety and efficacy of MDMA use
during psychotherapy in patients with chronic PTSD.
Study Design: This study is a double blind, phase 2 dose response trial performed in Boulder, CO
between October 2012 and February 2017. 77 candidates were recruited through internet ads and
referrals from mental health professionals. Further screening occurred over the telephone using a
scripted interview and in-person using a psychological assessment, physical exam, and
electrocardiogram. 28 participants were then selected based off of inclusion and exclusion criteria
(Table 6).
Before the trial, participants were interviewed by an independent rater to assess baseline
primary and secondary outcomes. The primary outcome assessed during this study was the CAPS
IV score, which is the gold-standard PTSD measurement. The secondary outcomes included
depression symptoms via Beck Depression Inventory-II (BDI-II), dissociation via Dissociative
Experiences Scale-II (DES-II), and sleep quality via Pittsburgh Sleep Quality Index (PSQI).
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Participants also underwent three 90-minute sessions with a therapy team member to establish a
comfortable therapeutic alliance before the MDMA sessions. Any psychiatric meds were tapered off
and discontinued before MDMA administration.

Inclusion Criteria

18 years and older
Physically healthy
PTSD duration of 6 months or more
CAPS score of ≥ 50
Failure to respond to or inability to tolerate at least 1 previous pharmacotherapy or
psychotherapy

Exclusion Criteria

Psychiatric or medical contraindications to treatment with MDMA
Pregnant or lactating women or women not using effective contraception

Table 6: Inclusion and exclusion criteria for Study 3 (Ot’alora, M. et. Al).

After preparation, participants were randomized through a web-based system into three
treatment groups: 40 mg of MDMA (“active” placebo), 100 mg of MDMA (active dose), and 125 mg
of MDMA (active dose). Each treatment group underwent two double-blind 8-hour psychotherapy
sessions a month apart. 90 minutes after the first dose, each participant was offered a supplemental
dose that was half the quantity of the initial dose. In order to assess the safety of MDMA,
participants ate dinner after the effects of MDMA resolved and remained in the clinic overnight.
Upon completing each experimental session, three integrative sessions were scheduled to
assess the participant’s psychological state and stability, as well as facilitate experiences during the
experimental sessions. The first integrative sessions occurred the morning after the experimental
session, while the following two integrative sessions were scheduled some time within a month. For
a week after each experimental session, participants were contacted daily over the telephone for a
15-60-minute call.
A month after the second experimental session, each participant was re-assessed by the
same independent rater to measure primary and secondary outcomes. Participants also completed
self-report measures. After collecting the primary endpoint data, the procedure was unblinded.
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Participants in the “active” placebo group were crossed over to the active dose group, then
participated in one preparatory session and three open-label sessions with associated integrative
sessions. Meanwhile, participants in the active dose groups had a third open-label session.
Participants were re-assessed to measure primary and secondary outcomes a month after the
second open-label session, two months after the third open-label session, and twelve months after
the final experimental session. Safety outcomes, including adverse events, adverse reactions, vital
signs, and suicidal ideations, were monitored throughout the treatment period. The primary and
secondary efficacy outcomes were deemed as the change from baseline to one month after the
second double-blind session. Both outcomes were analyzed via ANOVA with ⍺=0.05.
Study Results: Considering 2 participants discontinued treatment after the first experimental
session and 3 participants were removed due to discovery of secondary psychiatric diagnoses
during treatment, the researchers utilized both intention to treat (ITT) and per protocol (PP) to
analyze the primary outcome after the second double-blind experimental session (phase 1).
Utilizing the intention to treat analysis on the primary outcome, no statistically significant
differences were discovered. However, the active dose group assigned 125 mg of MDMA showed
the greatest reduction in PTSD symptom severity (Table 7). Utilizing the PP analysis on the primary
outcome, a statistical significant reduction in the CAPS-IV total scores was discovered when
comparing the 125 mg MDMA group with the “active” placebo group (Table 7). Furthermore, the
100 mg MDMA group displayed a trend towards significance compared to the “active” placebo
group.
For secondary outcomes, the researchers utilized ITT to analyze the following data points
after the second double-blind experimental session: the number of participants meeting diagnostic
criteria for PTSD, the percentage of participants with at least a 30% decrease in CAPS-IV total
scores, the change in depressive symptoms via BDI-II, the change in sleep quality via PSQI, and the
change in dissociative symptoms via DES-II. Overall, a large number of participants, especially in
the active dose groups, no longer met the diagnostic criteria for PTSD and experienced at least a
30% decrease in PTSD symptom severity (Table 8). Although not statistically significant, all groups
displayed a slight improvement in quality of sleep and the active dose groups reported fewer
dissociative experiences (Table 8). Participants did not display a change in depressive symptoms.
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ITT
MDMA group

40mg (“active”

Mean change (SD)

Analysis
P-value

PP
Mean change (SD)

in CAPS IV total

in CAPS IV total

score

score

Analysis
P-value

-11.5 (21.2)

N/A

-4 (11.9)

N/A

-24.4 (24.2)

0.36

-24.4 (24.2)

0.10

-26.3 (29.5)

0.27

-37 (20.9)

0.01

placebo)
100mg (active
dose)
125mg (active
dose)
Table 7: Primary Outcome – Mean change in CAPS IV total score from baseline to 1 month after the
2nd double-blind experimental session (phase 1) of MDMA assisted psychotherapy

Two months after the open-label sessions (phase 2), the researchers measured and
analyzed the primary and secondary outcomes once again. The “active” placebo group crossed over
to the active dose during open label sessions displayed a statistically significant decrease (p value =
0.01) in CAPS-IV total score after two open-label sessions with an active dose of MDMA. Also, four
out of the five participants (80%) experienced at least a 30% decrease in CAPS-IV total score and no
longer met diagnostic criteria for PTSD. Furthermore, the crossover group experienced a
statistically significant change in depression symptoms via BDI-II (p = 0.01) and dissociative
symptoms via DES-II (p = 0.04). Scores did not reveal a significant change two months after the
third open-label session for the crossover group.
Primary and secondary outcomes were recollected twelve months after each participant’s
last active dose of MDMA. The 12 month follow up data was compared to the baseline data and
revealed a statistically significant decrease in CAPS-IV total scores, decrease in depression
symptoms, decreased in dissociative symptoms, and increase in sleep quality (p < 0.0001).
Furthermore, 76% of participants no longer met PTSD diagnostic criteria.
Study Critique: Overall, the first phase of the study was a well-designed double-blind randomized
control trial. The patients were randomized through a computer system to minimize bias. Interrater bias was also eliminated by utilizing the same person to score each patient throughout the
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entire study. Furthermore, the independent rater was not involved in the experimental sessions, so
the possibility of guessing the participant’s assigned dosage and creating bias was minimal.

MDMA group

40mg (“active”

100mg (active dose)

placebo)
Participants NOT meeting PTSD

125mg (active
dose)

2 (33.3%)

4 (44.4%)

5 (41.7%)

1 (16.7%)

5 (55.6%)

6 (50%)

BDI-II change, mean (SD)

-11.5 (7.8)

-9.9 (13.3)

-11 (13.7)

PSQI change, mean (SD)

-0.8 (2.5)

-3.6 (6.2)

-2.0 (4.7)

DES-II change, mean (SD)

-0.2 (6.9)

-13.3 (15.3)

-5.9 (12)

diagnosis, number (percent)
Participants with ≥ 30%
decrease in CAPS-IV total score,
number (percent)

Table 8: Primary Outcome – Mean change in CAPS IV total score from baseline to 1 month after the
2nd double-blind experimental session (phase 1) of MDMA assisted psychotherapy

One issue with this study was the loss of four participants after initiating treatment.
Although most of the patients were removed from the study due to discovery of secondary
psychiatric diagnoses during treatment, loss of participants during a study can definitely skew data.
However, the researchers appropriately accounted for the loss of participants by utilizing both ITT
and PP to analyze the data. Another issue with the study is the low sample size and, therefore, the
low statistical power. Considering the amount of statistically significant findings and extremely low
p-values with such a small sample size, the credibility of this data is questionable. The final issue
with this study is the utilization of an open-label trial. The open-label trial with the crossover group
revealed the more statistically significant data than the both of the double-blind active dose groups,
which may be a concern for skewed data due to “placebo effect.” If the data from the open-label trial
was in fact skewed, then the final 12-month follow-up data collected would also be skewed.
However, in reality patients receiving MDMA-assisted psychotherapy would be aware of their
prescribed MDMA dosage, so the study’s results may still be applicable.
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Regardless of issues present, the study revealed data that MDMA-assisted psychotherapy
may be an extremely useful treatment for people with chronic PTSD. A large percentage of the
participants no longer met diagnostic criteria for PTSD and experienced a significant decrease in
PTSD symptom severity after treatment. Although research is still limited on this topic, MDMAassisted psychotherapy may become a useful resource for treating chronic PTSD, especially patients
also experiencing symptoms of depression, dissociation, and low sleep quality.
DISCUSSION
The focus of this statistical review is to determine the effectiveness of MDMA-assisted
psychotherapy in treating patients with chronic, refractory PTSD. Each of the three studies utilized
similar inclusion and exclusion criteria ensuring comparable sample populations. All three studies
also implemented at least two phases: a double-blind phase and an open-label phase. One of the
more significant differences in study design was the MDMA dose provided; however, the second
and third studies produced very similar data despite the slight difference in dosage.
Although the experiment designs were not exactly the same, the second and third studies
implemented very similar, yet improved designs from the first study that allowed for better data
collection. Considering study 1 was one of the earliest studies to utilize an “active” placebo dose
rather than an actual placebo, the data collection was more complicated and less inclusive to other
forms of measurement. Study 2 used a more thorough, yet simple form of data collection. However,
study 2 still had room for improvement because it did not include 12-month follow-up data due to
lack of placebo for comparison. Study 3 was the most recent and refined study analyzed for this
review. Study 3 had a very similar study layout and form of data collection as study 2; however,
study 3 included 12-month follow-up data and compared it to each individual patient’s baseline.
Further differences between the studies are noted in Table 9. Overall, the studies seemed to have
effectively minimized bias by decreasing inter-rater bias with independent interviewers and
decreasing intra-rater bias by utilizing each patient’s individual baseline for comparison.
Considering two of the three studies revealed statistically significant data while the other
study was trending towards significance, MDMA-assisted psychotherapy appears to be an effective
form of treatment for patients with chronic PTSD unresponsive to other forms of therapy. Both
studies 2 and 3 revealed statistically significant decreases in depression and dissociative symptoms,
as well as an increase in sleep quality. Considering that these are all characteristics of PTSD,
significant improvement in these realms is another outcome supporting the use of MDMA with
psychotherapy. Study 2 also discovered an increase in patient’s openness and willingness to discuss
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traumatic events after completing the experiment. With this mild change in personality, patients
were experiencing more significant improvements in psychological symptoms during therapy
sessions outside of this experiment. Therefore, MDMA-assisted psychotherapy may still contribute
to symptom improvement even long term.
Beyond the effectiveness of MDMA, the safety of MDMA needs to be assessed before its
application in PTSD treatment. Although one study did not reveal any serious drug-related adverse
side effects nor did it require medical intervention during or after the experimental sessions, the
other two studies revealed some serious adverse side effects and required medical intervention.
Some serious adverse side effects were reported including suicidal ideation and an increase in an
individual’s number of premature ventricular contractions. Although the most commonly reported
adverse side effects included anxiety, headache, fatigue, jaw clenching, muscle tension, and sleeprelated reactions. Most of the adverse side effects requiring medical intervention were psychiatric
in nature, mainly anxiety and depression with suicidal ideation. Some of the adverse side effects,
such as appendicitis, stage 1 breast cancer, ruptured ovarian cyst, and fractured lower limb
required, required medical intervention, but were deemed unrelated to the MDMA.
Overall, the main qualms with these studies are the slight differences in MDMA dose, small
sample sizes, use of open label trials, and lack of 12-month follow-up data. Open-label trials may
skew the data; however, they may be a more accurate representation of the results patients will
experience upon real-life application. Future studies with larger sample sizes and a study design
with data collection similar to study 3 need to be performed for further confirmation of this
statistically significant data. Considering the possible adverse side effects that may occur during
treatment with MDMA, researchers should consider excluding patients with a history of suicidal
ideation and contemplate the possible forms of treatment patients are able to receive for the
anxiety and sleep issues that may increase during treatment.

17

Nicole Blixt and Alexis Coleman

Study 1Oehen , P. et al

Study 2Mithoefer, M. et al

Study 3Ot’alora, M. et al

Sample size

N=12

N = 26 (22 veterans, 3
firefighters, 1 police officer)

N = 28

Study Outline

Double-blind trial
- Full dose (n=9)
- “Active” placebo (n=5)

Double-blind trial
- Full dose (n=19)
- “Active” placebo (n=7)

Double-blind trial
- Full dose (n=22)
- “Active” placebo (n=6)

Open label trial
- Full dose (n=7)

Open label trial
- Full dose (n=24)

Open label trial
- Full dose (n=26)

Intervention

125mg

75mg (n=7)
125mg (n=12)

100mg (n=9)
125mg (n=13)

Control

25mg

30mg

40mg

Follow-up

- Baseline
- 3 wks after 2nd doubleblind experimental session
- 3 wks after 3rd doubleblind experimental session
- 2, 6, and 12 months after
3rd double-blind
experimental session
-2, 6, and 12 months after
3rd open label trial

- Baseline
- 1 month after 2nd doubleblind experimental session
- 1 month after 2nd open label
trial
- 12 months after last active
dose of MDMA

- Baseline
- 1 month after 2nd doubleblind experimental session
- 2 months after open-label
experimental sessions
- 12 months after last active
dose of MDMA

Conclusion

Although the data was not
statistically significant, the
full dose group showed a
trend towards significance in
CAPS-IV total scores (p =
0.066).

Statistically significant
difference in CAPS-IV total
score in both active dose
groups (75 mg p = 0.0005, 125
mg p = 0.004) when comparing
baseline to 1 month after 2nd
experimental session.
Compared to the placebo
group, the active dose groups
showed a statistically
significant decrease in CAPS-IV
score (p = 0.001).

Using PP analysis, the 125 mg
active dose group compared to
the placebo group showed a
statistically significant
decrease in CAPS-IV total
scores (p = 0.01). After the
open label trial, the crossed
over group showed a
statistically significant
decrease in CAPS-IV (p value =
0.01). Furthermore, the 12
month follow up when
compared to baseline revealed
a statistically significant
decrease in CAPS-IV (p <
0.0001).

NNT*

N/A

2

2.8

Table 9: Comparison chart of all three studies utilized in this systematic review. *NNT to decrease
CAPS-IV total scores by ≥ 30% utilizing data from the active dose groups in the double-blind trial.
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CONCLUSION
These studies appear to demonstrate the effectiveness of MDMA-assisted psychotherapy in
PTSD patients who have previously failed other mainstay treatments. Two of the three articles
reached a statistical significance in the improvement of PTSD symptoms. The first article found
clinical improvement in their patients, but narrowly missed significance (p=0.066). Secondary
outcomes such as depression, sleep quality, and post-traumatic growth were significantly improved
in the MDMA active dose participants. Administration of the drug was done safely with minimal
adverse effects. Vitals were closely watched in all of the articles. All three of these articles are
double blind randomized control trials that suffered from small sample sizes. An unforeseen
observation and statistical data of the active placebo group revealed the counter-therapeutic effects
of partial activation of MDMA suggesting that the correct dose of MDMA is crucial to its potential
benefits. This is a growing field and many new studies have been done since the 2013 pilot study.
There has been a total of 6 phase 2 trial studies showing similar significant results,
including 2 of the articles listed above. This has been the foundation for the continuation onto
phase 3 trials. FDA granted “Breakthrough Therapy” for MDMA-assisted psychotherapy for PTSD
patients that accelerate the drug development process. The upcoming phase 3 trials will enroll
about 200-300 participants, addressing the small sample size limitation in previous studies. If the
phase 3 trials can replicate the results of phase 2, PTSD patients will be able to use MDMA-assisted
psychotherapy for treatment. The implication of these findings are important for chronic PTSD
patients refractory to other medications. MDMA-assisted psychotherapy is a breakthrough
treatment for PTSD but the time, money, and resources are potential concerns for the clinical
application in the future.
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